Basel,?November 6,?2020?? Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)⁶. The ongoing trial failed to meet its primary endpoint showing that treatment with canakinumab plus standard of care (SoC) did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus SoC up to Day 29¹. The trial did not meet its key secondary endpoint of reducing the COVID-19-related death rate during the 4-week period after treatment¹. The safety profiles of canakinumab plus SoC and placebo plus SoC were comparable¹. ?Though the CAN-COVID trial did not show the patient benefit we were hoping for, it helps improve the scientific understanding of COVID-19 and the role of interleukin-1? inhibition,? said John Tsai, M.D., Head of Global Drug Development and Chief Medical Officer for Novartis. ?There?s still an urgent need for effective ways to combat COVID-19 and we will continue to apply our best scientific minds in support of the global pandemic response, including a Phase III trial of ruxolitinib. We?re deeply grateful to the patients who participated and their caregivers, as well as the healthcare professionals and hospital staff who made this research possible while fighting the pandemic on the front line.? In the trial, the primary endpoint of survival without the need for mechanical ventilation was 88.8% for canakinumab plus SoC vs 85.7% for placebo plus SoC (P=0.29)¹. The key secondary endpoint of COVID-19-related mortality up to 4 weeks was 4.9% for canakinumab plus SoC vs 7.2% for placebo plus SoC (P=0.33)¹. Both the primary and key secondary endpoints trended in favor of canakinumab but did not reach statistical significance¹. No new safety signals for canakinumab were identified¹. This interim analysis will be submitted to a peer-reviewed journal in the coming weeks. The CAN-COVID results do not affect any other ongoing trials for canakinumab, including investigations for the treatment of non-small cell lung cancer (NSCLC)^7-9. As part of its continued efforts to support the global pandemic response, Novartis in October announced a collaboration with Switzerland-based Molecular Partners to develop two DARPin^??therapies designed for potential use against COVID-19⁴. In addition, a Phase III trial for ruxolitinib in COVID-19 is ongoing, with preliminary results expected by year end⁵. About CAN-COVID CAN-COVID is a Phase III, multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of canakinumab plus standard of care (SoC) in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)⁶. Patients were hypoxic but not requiring intubation or invasive mechanical ventilation⁶. The primary endpoint was to demonstrate the benefit of canakinumab plus SoC vs placebo plus SoC in increasing the chance of survival without the need for invasive mechanical ventilation up to Day 29⁶. The key secondary endpoint was to reduce the COVID-19-related death rate during the 4-week period after trial treatment⁶. The trial enrolled 454 patients at multiple centers across the US, Russia and Europe¹. Both endpoints were analyzed at Day 29⁶. The average age of trial participants was 58 years old, ranging from 18 to 98 years old¹. Approximately 30% were Hispanic or Latino, 16% were Black or African American and 4% were Asian¹. Interim analysis of Day 29 results is available. The trial is ongoing (to Day 127) with full results expected in early 2021⁶. About canakinumab Canakinumab is biologic medicine used in the treatment of a number of rare, debilitating auto-inflammatory diseases, for which there are limited options available. It is a monoclonal antibody that binds to and neutralizes interleukin-1 beta (IL-1?), blocking its action^2,3,10. Excessive production of IL-1? plays a prominent role in certain inflammatory diseases and immune responses^11,12. Canakinumab is an established medicine approved under the trade name Ilaris^??in approximately 60 countries including the US, Europe and others. It is indicated for rare conditions including periodic fever syndromes, adult-onset Still?s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA)^2,3. First approved in 2009, canakinumab has been proven to be highly effective and well tolerated as a treatment option for its approved indications based on previously reported clinical trials^2,3. As well as being studied in severe COVID-19, canakinumab is also being investigated for the treatment of a number of other diseases involving inflammation, including non-small cell lung cancer (NSCLC)^7-9. Novartis response to COVID-19?pandemic Novartis is making multiple contributions to the global effort to combat the COVID-19 pandemic and support the stability of global healthcare systems. The company has committed to donating USD 40 million to support communities around the world impacted by the pandemic. In addition, Novartis is active in several key cross-industry research initiatives, the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard as well as a COVID-19 directed partnership supported by the Innovative Medicines Initiative (IMI)¹³. Novartis has also announced a collaboration with Molecular Partners to develop two DARPin^??therapies designed for potential use against COVID-19, and the company is separately supporting COVID-19-related clinical investigations of several Novartis medicines⁴. We continue with the Phase III trial for ruxolitinib, another Novartis medicine, in collaboration with Incyte⁵. Preliminary results from this trial are expected by year end. Two medicines in early stage development are also being investigated focusing on stopping or slowing the body?s overactive immune response to COVID-19^{14, 15}. In our labs, we have started a collaborative, longer-term drug discovery effort to develop an antiviral molecule to potentially treat all coronaviruses. To sustain access, the Novartis generics and biosimilars division Sandoz became the first company to commit to keeping stable prices for a basket of essential medicines that may help in the treatment of COVID-19 and entered into a partnership with US-based Civica Rx to support stable supply of essential generic hospital medicines. We are making 15 drugs that treat key symptoms of COVID-19 available to low- and lower-middle income countries at zero profit until a vaccine or curative treatment is found. This includes dexamethasone, which is the only medicine shown to decrease mortality so far in severe hospitalized COVID pneumonia¹³. Furthermore, Novartis Gene Therapies entered into a manufacturing agreement with Massachusetts Eye and Ear and Massachusetts General Hospital to produce its novel genetic COVID-19 vaccine candidate called AAVCOVID¹⁶. More information about the Novartis response to COVID-19 is available at?www.Novartis.com/coronavirus Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as ?potential,? ?can,? ?will,? ?plan,? ?may,? ?could,? ?would,? ?expect,? ?anticipate,? ?seek,? ?look forward,? ?believe,? ?committed,? ?investigational,? ?pipeline,? ?launch,? or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG?s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is reimagining medicine to improve and extend people?s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world?s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at?https://www.novartis.com. Novartis is on Twitter. Sign up to follow @Novartis at?https://twitter.com/novartisnews For Novartis multimedia content, please visit?https://www.novartis.com/news/media-library For questions about the site or required registration, please contact?media.relations@novartis.com References

1.	Novartis Data on File 2020.
2.	Novartis Pharmaceuticals Corporation. Ilaris??(canakinumab): US Prescribing Information [online] September 2020. Available from:?https://www.novartis.us/sites/www.novartis.us/files/ilaris.pdf?[Last accessed: November 2020].
3.	Novartis Pharmaceuticals UK Ltd. Ilaris??(canakinumab): Summary of Product Characteristics [online] March 13, 2020. Available from:?https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_en.pdf?[Last accessed: November 2020].
4.	Novartis Media Release. Novartis announces collaboration with Molecular Partners to develop two DARPin??therapies designed for potential use against COVID-19 [online] October 28, 2020. Available from:?https://www.novartis.com/news/media-releases/novartis-announces-collaboration-molecular-partners-develop-two-darpin-therapies-designed-potential-use-against-covid-19?[Last accessed: November 2020].
5.	ClinicalTrials.gov. Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID). NCT04362137. Available from:?https://clinicaltrials.gov/ct2/show/NCT04362137?[Last accessed: November 2020].
6.	Clinicaltrials.gov. Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia (CAN-COVID). NCT04362813. Available from:?https://clinicaltrials.gov/ct2/show/NCT04362813?[Last accessed: November 2020].
7.	ClinicalTrials.gov. Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1). NCT03631199. Available from:?https://clinicaltrials.gov/ct2/show/NCT03631199?[Last accessed: November 2020].
8.	ClinicalTrials.gov. Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2). NCT03626545. Available from:?https://clinicaltrials.gov/ct2/show/NCT03626545?[Last accessed: November 2020].
9.	ClinicalTrials.gov. Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer (CANOPY-A). NCT03447769. Available from:?https://clinicaltrials.gov/ct2/show/NCT03447769?[Last accessed: November 2020].
10.	Rondeau JM, Ramage P, Zurini M, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta.?MAbs. 2015;7(6):1151-1160.
11.	Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.?Immunity. 2004;20(3):319-325.
12.	Park YH, Wood G, Kastner DL, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS.?Nat Immunol. 2016;17(8):914-921.
13.	Novartis.com. COVID-19 Novartis response. Available from:?https://www.novartis.com/coronavirus/response?[Last accessed: November 2020].
14.	Clinical trials.gov. Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia. NCT04382053. Available from:?https://clinicaltrials.gov/ct2/show/NCT04382053?[Last accessed: November 2020].
15.	Clinical trials.gov. Study of Efficacy and Safety of MAS825 in Patients With COVID-19 (MAS-COVID). NCT04382651. Available from:?https://clinicaltrials.gov/ct2/show/NCT04382651?[Last accessed: November 2020].
16.	Novartis Media Release. AAVCOVID vaccine program from Mass. Eye and Ear and Mass General Enters Manufacturing Agreement with Gene Therapy Leader AveXis, a Novartis Company [online] May 28, 2020. Available from:?https://masseyeandear.org/news/press-releases/2020/05/aavcovid-vaccine-program-enters-manufacturing-agreement-with-avexis?[Last accessed: November 2020].

# # #

Novartis Media Relations E-mail:?media.relations@novartis.com

Antonio Ligi Novartis External Communications +41 61 324 1374 antonio.ligi@novartis.com Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com

Louise Clark Novartis Pharma Communications +41 723 3681 (mobile) louise.clark@novartis.com

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail:?investor.relations@novartis.com

Central		North America
Samir Shah	+41 61 324 7944	Sloan Simpson	+1 862 778 5052
Thomas Hungerbuehler Isabella Zinck	+41 61 324 8425 +41 61 324 7188